Non-invasive blood glucose monitoring device shows positive results in
trials
18 November 2005
Boulder, Colorado, USA. Israeli start-up company Glucon announced the
recent trial results of its flagship product, Aprise, a continuous,
non-invasive, glucose monitoring device. The results were presented at the
Fifth Annual Diabetes Technology Meeting in San Francisco, and at Medica in
Dusseldorf, this week.
The device works by illuminating tissue with laser light of several
selected wavelengths that can specifically detect glucose. The illuminated
tissue produces ultrasound waves which are picked up by an acoustic detector
placed on the skin. The acoustic analysis can remove the influence of the
outer layers of the skin and produce a measure of blood volume.
"Three different protocols were employed to test Aprise. In the first
protocol rapid glucose variations were induced by venous infusion of
dextrose solution and insulin. In the second protocol, the glucose level was
increased by drinking a glucose solution and decreased by the diabetic
subject's regular medications. And in the third protocol the glucose level
was raised with a regular meal and decreased again by the diabetic subject's
regular medications. Thirty subjects participated in the studies. The
prospective results were a Mean Absolute Relative Deviation of 19%,"
explained Dr. Benny Pesach.
"There are several companies in the glucose monitoring space racing to
develop an accurate, non-invasive system. Data collected with Glucon's
Aprise showed that the technology has surpassed that of the competition in
terms of accuracy and speed. Glucon's Aprise provides a glucose measurement
every three seconds. It is also light weight, compact, comfortable,
impressively accurate and the most clinically advanced," said Glucon
President Mr. Ron Nager.
The device is still under development and is not yet available
commercially.
Glucon also announced that the Company has secured an option to license
several photoacoustic technology patents, granted to a group of scientists
at the University of Texas Medical Branch in Galveston.
Links
Glucon website: www.glucon.com
Clinical results for Aprise:
www.glucon.com/main.asp?t=5
To top
|